Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more
Market Cap & Net Worth: Aardvark Therapeutics, Inc. Common Stock (AARD)
Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) has a market capitalization of $116.05 Million ($116.05 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20458 globally and #7427 in its home market, demonstrating a -12.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aardvark Therapeutics, Inc. Common Stock's stock price $5.33 by its total outstanding shares 21773272 (21.77 Million).
Aardvark Therapeutics, Inc. Common Stock Market Cap History: 2025 to 2026
Aardvark Therapeutics, Inc. Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $285.77 Million to $116.05 Million (0.00% CAGR).
Index Memberships
Aardvark Therapeutics, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #564 of 976 |
Weight: Aardvark Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aardvark Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aardvark Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AARD by Market Capitalization
Companies near Aardvark Therapeutics, Inc. Common Stock in the global market cap rankings as of March 19, 2026.
Key companies related to Aardvark Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aardvark Therapeutics, Inc. Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Aardvark Therapeutics, Inc. Common Stock's market cap moved from $285.77 Million to $ 116.05 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $116.05 Million | -59.39% |
| 2025 | $285.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Aardvark Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.05 Million USD |
| MoneyControl | $116.05 Million USD |
| MarketWatch | $116.05 Million USD |
| marketcap.company | $116.05 Million USD |
| Reuters | $116.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.